Pb2161: bortezomib, pomalidomide, and dexamethasone is an effective regimen for patients with relapse and refractory al amyloidosis and monoclonal immunoglobulin deposition disease

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: There needs for treatment of recurrent and refractory amyloidosis or monoclonal immunoglobulin deposition disease (MIDD) are still unmet. Aims: The efficacy and safety of treatment with bortezomib, pomalidomide, and dexamethasone (BPd) as second-line treatment for AL amyloidosis or MIDD were reported. Methods: Recurrent or refractory primary AL/AHL amyloidosis amyloidosis or MIDD patients receiving BPd from Jan 2021 to March 2022 were retrospectively collected. Results: Twenty-one patients were treated for a median of 3 cycles (range, 1-8). The median difference between involved and uninvolved free light chains (dFLC) before BPd initiation was 111.2 (IQR, 62.8-885.0), with a decrease in median value of 19 (IQR: 7.0-122.3). 14/21 patients had a hematologic response, with 3/21 complete response, 9/21 very good partial response, with 7 of these 21 patients achieving an organ response. Toxicity was minimal and no patient had a treatment-related death. During a median follow-up period of five months one patient died of chocking and suffocation.Summary/Conclusion: BPd is well tolerated with few side effects and warrants continued investigation as a treatment for AL amyloidosis. Keywords: Amyloidosis